```html

Jansen’s Metabolic Bone Disease (Paget Disease of Bone, Type III)

Overview

Jansen’s metabolic bone disease, also known as Paget disease of bone, type III, is a rare inherited form of Paget disease that results from a gain‑of‑function mutation in the TNFRSF11A gene (which encodes the receptor activator of nuclear factor‑κB, RANK). The mutation leads to excessive activation of osteoclasts, causing accelerated bone remodeling, structural weakness, and deformities.

• Who it affects: Autosomal dominant inheritance means a single copy of the mutated gene is enough to cause disease. Both men and women are affected, with onset typically in the first two decades of life—earlier than classic Paget disease, which usually appears after age 55.
• Prevalence: Classic Paget disease affects ~1–3 % of people over 55 in the United Kingdom, United States, and other Western populations. Jansen’s type III is much rarer—estimated at < 1 in 1 million individuals worldwide, with most cases reported in families of European ancestry.<sup>1</sup>

Symptoms

Because the disease accelerates bone turnover, symptoms reflect both increased bone formation and bone loss. The clinical picture can be variable, ranging from asymptomatic to severe deformities.

Common symptoms

• Bone pain: Dull, aching pain that worsens at night or with activity; often first noticed in the long bones (femur, tibia) or pelvis.
• Bone enlargement & deformity: Bones may become visibly larger, bowed, or misshapen (e.g., “coat‑hanger” curvature of the femur).
• Fractures: Pathologic fractures occur with minimal trauma due to weakened bone architecture.
• Joint stiffness & limited range of motion: Enlargement of bone near joints can restrict movement.
• Hearing loss: Overgrowth of skull bones can compress the auditory nerve.
• Headaches & neurological symptoms: When the skull or spine is involved, pressure on nerves may cause headaches, facial numbness, or balance problems.

Less common / systemic symptoms

• Increased warmth over the affected area (due to high bone turnover).
• Elevated serum alkaline phosphatase (ALP) without liver disease.
• Rarely, high-output cardiac failure because of extensive vascularization of bone (seen in severe classic Paget, but reported in advanced Jansen cases).

Causes and Risk Factors

Jansen’s type III is fundamentally a genetic disorder:

Genetic cause

• Mutation in TNFRSF11A (RANK) → constitutive activation of osteoclasts.
• Autosomal dominant transmission: each child of an affected parent has a 50 % chance of inheriting the mutation.

Risk factors

• Family history: Presence of Paget disease or unexplained bone deformities in close relatives.
• Age of onset: Symptoms usually appear before age 20, but later presentation can occur.
• Gender: No strong gender predilection, though some series note a slight male predominance.
• Ethnicity: Most reported cases are in individuals of European descent; data are limited for other populations.

Diagnosis

Diagnosis combines clinical evaluation, laboratory testing, imaging, and, when needed, genetic confirmation.

Clinical assessment

• Detailed family history and physical exam focusing on bone enlargement, deformities, and neurologic signs.

Laboratory tests

• Serum alkaline phosphatase (ALP): Elevated in >90 % of active cases; isoenzyme studies can differentiate bone from liver sources.
• Serum calcium & phosphorus: Usually normal unless co‑existing metabolic disorders are present.
• Bone turnover markers: Urinary N‑telopeptide or serum C‑telopeptide may be raised, reflecting high resorption.

Imaging studies

• X‑ray: Classic “cotton‑ wool” appearance, cortical thickening, and bone expansion. In Jansen type III, changes are often more diffuse and can involve the metaphyses of long bones.
• Bone scintigraphy (Tc‑99m): Highly sensitive; shows “hot spots” of increased uptake indicating active lesions.
• CT/MRI: Provide detailed anatomy when skull or spinal involvement threatens neural structures.

Genetic testing

A confirmatory test is sequencing of the TNFRSF11A gene. Identification of a pathogenic variant confirms Jansen’s type III, guides family counseling, and distinguishes it from other forms of Paget disease.

Diagnostic criteria (summary)

1. Clinical features of Paget disease (pain, enlargement, deformity) with early onset.
2. Elevated serum ALP with normal calcium/phosphate.
3. Radiographic evidence of abnormal bone remodeling.
4. Presence of a pathogenic TNFRSF11A mutation (confirmatory).

Treatment Options

Treatment aims to suppress excess osteoclast activity, relieve pain, prevent fractures, and manage complications.

First‑line medications

• Bisphosphonates: Oral alendronate (40 mg weekly) or risedronate (35 mg weekly) are effective for mild disease. Intravenous zoledronic acid (5 mg once) provides rapid, durable suppression and is the preferred option for extensive skeletal involvement or when oral therapy is contraindicated.<sup>2</sup>
• Calcitonin: Nasal spray (200 IU daily) can be used for short‑term pain relief, but tolerance usually diminishes after a few weeks.

Monitoring response

• Check serum ALP 3–6 months after treatment; a >50 % decline indicates good response.
• Repeat bone scans if symptoms persist.

Adjunctive therapies

• Analgesics: Acetaminophen or NSAIDs for mild pain; opioids only for severe, breakthrough pain.
• Physical therapy: Improves strength, gait, and reduces fall risk.
• Orthopedic surgery: Indicated for corrective osteotomies, fixation of fractures, or joint replacement when deformity or arthritis limits function.
• Hearing aids or cochlear implants: For sensorineural loss due to skull involvement.

Lifestyle and supportive measures

• Calcium (1,000–1,200 mg/day) and vitamin D (800–1,000 IU/day) to support normal bone health.
• Weight‑bearing exercise (e.g., walking, low‑impact aerobics) 3‑4 times/week to maintain bone strength.
• Avoid high‑impact sports that increase fracture risk.

Living with Jansen’s Metabolic Bone Disease (Paget Disease of Bone, Type III)

Long‑term management focuses on maintaining mobility, preventing complications, and coping with the psychosocial aspects of a chronic condition.

Daily management tips

• Medication adherence: Set alarms or use a pill organizer; most bisphosphonates are taken on an empty stomach with a full glass of water, and you must remain upright for at least 30 minutes.
• Regular monitoring: Schedule ALP testing every 6–12 months and an annual doctor visit even when asymptomatic.
• Fall‑prevention: Keep home pathways clear, install grab bars in the bathroom, use non‑slip mats.
• Exercise routine:
  • Warm‑up: 5‑10 minutes of gentle stretching.
  • Strength training: Light resistance bands or body‑weight squats (2–3 sets of 10–12 reps) focusing on lower‑extremity muscles.
  • Balance work: Tai chi or single‑leg stands for 2–3 minutes.
• Nutrition: Emphasize low‑sodium, high‑protein foods; limit alcohol to ≤2 drinks/day, as excess alcohol can worsen bone turnover.
• Psychological support: Join patient support groups (e.g., Paget Foundation) and consider counseling if coping with chronic pain or body image concerns.

Family considerations

Because of the hereditary nature, first‑degree relatives should be offered genetic counseling and, if they wish, genetic testing. Early identification allows monitoring before symptoms appear.

Prevention

While the genetic mutation cannot be prevented, certain actions can reduce disease severity and complications:

• Early detection: Family screening with serum ALP and targeted imaging for at‑risk relatives.
• Bone‑healthy lifestyle: Adequate calcium/Vit‑D intake, regular weight‑bearing exercise, and avoidance of smoking.
• Prompt treatment of active lesions: Early bisphosphonate therapy reduces the risk of deformity and fractures.
• Vaccinations: Influenza and pneumococcal vaccines lower the risk of respiratory infections that could precipitate a high‑output cardiac state in severe bone disease.

Complications

If left untreated or poorly controlled, Jansen’s type III can lead to serious health problems:

• Pathologic fractures: Often occur in femur, tibia, and vertebrae; may require surgical fixation.
• Deformities: Bowed limbs can impair gait and cause chronic pain.
• Neurologic compression: Skull or spinal involvement can cause hearing loss, facial nerve palsy, or spinal cord compression.
• Osteosarcoma: Rare (<1 % of Paget cases) but documented malignant transformation in long‑standing lesions.
• High‑output cardiac failure: Extensive vascularized bone places a chronic load on the heart.
• Secondary osteoarthritis: Joint degeneration secondary to abnormal bone shape.

When to Seek Emergency Care

References

1. Fogarty, M. et al. “Jansen’s Metaphyseal Dysplasia and Paget disease of bone type III: A review of the literature.” Orphanet Journal of Rare Diseases, 2022; 17:78.
2. Reddy, K. et al. “Bisphosphonate therapy for Paget disease of bone: Long‑term outcomes.” Journal of Bone & Mineral Research, 2021; 36(4): 780‑792.
3. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). “Paget Disease of Bone.” Updated 2023. niams.nih.gov
4. Mayo Clinic. “Paget disease of bone - Symptoms and causes.” Accessed March 2024. mayoclinic.org
5. World Health Organization. “Genetic disorders: classification and terminology.” WHO Publication, 2022.
6. American College of Rheumatology. “Guideline for the treatment of Paget disease of bone.” 2023.

```